Reviewing Cronos Group Inc. (CRON)’s and Hepion Pharmaceuticals Inc. (NASDAQ:CTRV)’s results

This is therefore a comparing of the profitability, analyst recommendations, risk, institutional ownership, dividends, earnings and valuation in Cronos Group Inc. (NASDAQ:CRON) and Hepion Pharmaceuticals Inc. (NASDAQ:CTRV). The two are both Biotechnology companies that compete with one another.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Cronos Group Inc. 16 0.00 N/A -0.03 0.00
Hepion Pharmaceuticals Inc. 11 0.00 N/A -81.90 0.00

In table 1 we can see Cronos Group Inc. and Hepion Pharmaceuticals Inc.’s gross revenue, earnings per share (EPS) and valuation.


Table 2 shows the net margins, return on assets and return on equity of the two firms.

Net Margins Return on Equity Return on Assets
Cronos Group Inc. 0.00% 0% 0%
Hepion Pharmaceuticals Inc. 0.00% 0% 0%

Analyst Recommendations

The following table shown below contains the ratings and recommendations for Cronos Group Inc. and Hepion Pharmaceuticals Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Cronos Group Inc. 0 2 2 2.50
Hepion Pharmaceuticals Inc. 0 0 0 0.00

The consensus price target of Cronos Group Inc. is $19.75, with potential upside of 71.29%.

Institutional & Insider Ownership

Roughly 9.35% of Cronos Group Inc. shares are owned by institutional investors while 3.72% of Hepion Pharmaceuticals Inc. are owned by institutional investors. Cronos Group Inc.’s share owned by insiders are 48.28%. Competitively, Hepion Pharmaceuticals Inc. has 36.42% of it’s share owned by insiders.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Cronos Group Inc. -10.5% -13.8% -19.05% -25.07% 133.28% 32.92%
Hepion Pharmaceuticals Inc. -7.01% -16.55% -75.65% -84.73% -94.67% -81.86%

For the past year Cronos Group Inc. has 32.92% stronger performance while Hepion Pharmaceuticals Inc. has -81.86% weaker performance.


Cronos Group Inc. beats Hepion Pharmaceuticals Inc. on 4 of the 4 factors.

Cronos Group Inc., formerly known as PharmaCan Capital Corp., is a principal investment firm. The firm seeks to invest in companies either licensed, or actively seeking a license, to produce medical marijuana pursuant to Canada's Marihuana for Medical Purposes Regulations (?MMPR?). The firm typically invests in companies based in Canada. The firm is primarily an equity investor, may also advance debt as appropriate. It seeks to make minority investments with appropriate governance and shareholder rights. The firm seeks board representation consistent with the size of the investment, but does not need control. Cronos Group Inc. was incorporated in January, 2013 and is based in Toronto, Canada with an additional office in in Toronto, Canada.

ContraVir Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the development of antiviral drugs with a primary emphasis on the treatment of Hepatitis B virus (HBV) infections. The company is developing CMX157 and CRV431 to treat HBV infection; and FV-100, an orally available, small molecule compound for the prevention of post-herpetic neuralgia, and treatment of herpes zoster infection and acute zoster-associated pain. ContraVir Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Edison, New Jersey.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.